919 related articles for article (PubMed ID: 25934946)
1. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial.
Syková E; Rychmach P; Drahorádová I; Konrádová Š; Růžičková K; Voříšek I; Forostyak S; Homola A; Bojar M
Cell Transplant; 2017 Apr; 26(4):647-658. PubMed ID: 27938483
[TBL] [Abstract][Full Text] [Related]
3. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study.
Kim HY; Kim H; Oh KW; Oh SI; Koh SH; Baik W; Noh MY; Kim KS; Kim SH
Stem Cells; 2014 Oct; 32(10):2724-31. PubMed ID: 24966156
[TBL] [Abstract][Full Text] [Related]
4. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
6. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.
Oh KW; Noh MY; Kwon MS; Kim HY; Oh SI; Park J; Kim HJ; Ki CS; Kim SH
Ann Neurol; 2018 Sep; 84(3):361-373. PubMed ID: 30048006
[TBL] [Abstract][Full Text] [Related]
7. Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis.
Siwek T; Jezierska-Woźniak K; Maksymowicz S; Barczewska M; Sowa M; Badowska W; Maksymowicz W
Med Sci Monit; 2020 Dec; 26():e927484. PubMed ID: 33301428
[TBL] [Abstract][Full Text] [Related]
8. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study.
Prabhakar S; Marwaha N; Lal V; Sharma RR; Rajan R; Khandelwal N
Neurol India; 2012; 60(5):465-9. PubMed ID: 23135021
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Safety of Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis: A Pilot Study.
Shamsaei G; Houshmand F; Ahmadzadeh Deylami A; Valizadeh A; Rafie S; Moradi M
Adv Pharm Bull; 2023 Mar; 13(2):361-367. PubMed ID: 37342380
[No Abstract] [Full Text] [Related]
10. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS.
Staff NP; Madigan NN; Morris J; Jentoft M; Sorenson EJ; Butler G; Gastineau D; Dietz A; Windebank AJ
Neurology; 2016 Nov; 87(21):2230-2234. PubMed ID: 27784774
[TBL] [Abstract][Full Text] [Related]
11. Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial.
Nabavi SM; Arab L; Jarooghi N; Bolurieh T; Abbasi F; Mardpour S; Azimyian V; Moeininia F; Maroufizadeh S; Sanjari L; Hosseini SE; Aghdami N
Cell J; 2019 Jan; 20(4):592-598. PubMed ID: 30124008
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis.
Tavakol-Afshari J; Boroumand AR; Farkhad NK; Adhami Moghadam A; Sahab-Negah S; Gorji A
Regen Ther; 2021 Dec; 18():268-274. PubMed ID: 34466632
[TBL] [Abstract][Full Text] [Related]
13. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients.
Kwon MS; Noh MY; Oh KW; Cho KA; Kang BY; Kim KS; Kim YS; Kim SH
J Neurochem; 2014 Oct; 131(2):206-18. PubMed ID: 24995608
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.
Nam JY; Lee TY; Kim K; Chun S; Kim MS; Shin JH; Sung JJ; Kim BJ; Kim BJ; Oh KW; Kim KS; Kim SH
Trials; 2022 May; 23(1):415. PubMed ID: 35585556
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
16. Stem cell transplantation into the intraventricular space via an Ommaya reservoir in a patient with amyotrophic lateral sclerosis.
Baek W; Kim YS; Koh SH; Lim SW; Kim HY; Yi HJ; Kim H
J Neurosurg Sci; 2012 Sep; 56(3):261-3. PubMed ID: 22854595
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Gotkine M; Caraco Y; Lerner Y; Blotnick S; Wanounou M; Slutsky SG; Chebath J; Kuperstein G; Estrin E; Ben-Hur T; Hasson A; Molakandov K; Sonnenfeld T; Stark Y; Revel A; Revel M; Izrael M
J Transl Med; 2023 Feb; 21(1):122. PubMed ID: 36788520
[TBL] [Abstract][Full Text] [Related]
18. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis.
Mazzini L; Mareschi K; Ferrero I; Vassallo E; Oliveri G; Boccaletti R; Testa L; Livigni S; Fagioli F
Neurol Res; 2006 Jul; 28(5):523-6. PubMed ID: 16808883
[TBL] [Abstract][Full Text] [Related]
19. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.
Berry JD; Cudkowicz ME; Windebank AJ; Staff NP; Owegi M; Nicholson K; McKenna-Yasek D; Levy YS; Abramov N; Kaspi H; Mehra M; Aricha R; Gothelf Y; Brown RH
Neurology; 2019 Dec; 93(24):e2294-e2305. PubMed ID: 31740545
[TBL] [Abstract][Full Text] [Related]
20. A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting Phase I human trials.
Chen BK; Staff NP; Knight AM; Nesbitt JJ; Butler GW; Padley DJ; Parisi JE; Dietz AB; Windebank AJ
Transfusion; 2015 May; 55(5):1013-20. PubMed ID: 25413276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
